Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/jcm10020250
Keywords
TRPM8 agonist; cryosim-3; dry eye; neuropathic pain
Categories
Funding
- Technology Innovation Program - Ministry of Trade, Industry & Energy (MOTIE, Korea) [20009481]
- Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HR20C0021050020]
- Chonnam National University Hospital Biomedical Research Institute [BCRI 20072]
- Korea Evaluation Institute of Industrial Technology (KEIT) [20009481] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- Korea Health Promotion Institute [HR20C0021050020] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
TRPM8 agonist (C3) showed effectiveness in relieving DE-associated NOP, improving eye pain intensity, quality of life, associated factors, and Schirmer test scores in a 1-month pilot study on 15 patients.
Background: Activation of TRPM8, a cold-sensing receptor located on the cornea and eyelid, has the potential to relieve the neuropathic ocular pain (NOP) in dry eye (DE) by inhibiting other aberrant nociceptive inputs. We aimed to investigate the effect of a topical TRPM8 agonist, cryosim-3 (C3), on relieving DE-associated NOP. Methods: We conducted a prospective pilot study of 15 patients with DE-associated NOP. These patients applied topical C3 to their eyelid, 4 times/day for 1 month. The patients underwent clinical examinations. They also completed the Ocular Pain Assessment Survey (OPAS), which is a validated questionnaire for NOP, at baseline, 1 week, and 1 month after treatment. Result: At 1 week, the OPAS scores of eye pain intensity, quality of life (driving/watching TV, general activity, sleep, and enjoying life/relations with other people), and associated factors (burning sensation, light sensitivity, and tearing) improved. The total OPAS scores of eye pain intensity, quality of life, and associated factors remained improved at 1 month. The Schirmer test scores also improved at 1 month. Conclusion: TRPM8 agonist (C3) could be a novel agent for treating patients with DE-associated NOP who are unresponsive to conventional treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available